Background: Cardiovascular disease is the leading cause of death in renal transplant recipients. An association between haptoglobin genotype 2-2 and cardiovascular disease has been found in patients with diabetes mellitus and liver transplant recipients. To date, the role of haptoglobin genotype after renal transplantation has not been studied. Methods: In this single-center retrospective cohort study of 1975 adult Norwegian transplant recipients, who underwent transplantation between 1999 and 2011, we estimated the risk of all-cause and cardiovascular mortality and overall and death-censored graft loss for patients with haptoglobin genotype 2-2 compared to genotype 2-1 or 1-1, after adjustment for confounders and competing risks. Results: We found no associations between haptoglobin genotype 2-2 and cardiovascular mortality (subdistributional hazard ratio 1.08, 95% confidence interval 0.78-1.49; P ¼ .63). We also failed to detect any association between haptoglobin 2-2 genotype and all-cause mortality, overall graft loss, and death-censored graft loss. Similar results were found in the subpopulation of transplant recipients with diabetes. Conclusion: In this large cohort of kidney transplant recipients, we could not demonstrate any association between haptoglobin 2-2 genotype and patient or graft survival after renal transplantation.
Introduction
Cardiovascular disease (CVD) contributes to two-third of all deaths worldwide 1 and is the major cause of death in renal transplant recipients. 2 Oxidative stress induces endothelial dysfunction and increases the risk of CVD. 3, 4 Several pro-and antioxidative pathways act simultaneously. When hemoglobin (Hb) is released from erythrocytes during intravascular hemolysis, its detoxifier haptoglobin (Hp) binds the free Hb, and the Hp-Hb complex is cleared from the circulation by the macrophage CD163 receptor. 5 Free Hb becomes highly toxic through the release of free iron generating reactive oxygen species, initiating and enhancing atherosclerosis. 5 Due to genetic polymorphism, Hp 1-1, 2-1, and 2-2 genotype, Hp proteins are functionally different in different individuals. 6 The Hp 2 proteins are not cleared from the circulation by the macrophage CD163 receptor as efficiently as Hp 1 proteins. 6 Consequently, individuals with the Hp 2-2 genotype are less protected against Hb-induced oxidative damage than individuals expressing Hp 1-1 or 2-1 genotypes. 7 In addition to Hp-Hb complex clearance by macrophages, renal proximal tubule cells can also clear the Hp-Hb complex. 6 However, renal clearance of the Hp-Hb complex may cause increased iron concentration in the proximal tubular cells, leading to tubular damage, collagen deposition, and ultimately fibrosis. This mode of clearance mostly occurs in Hp 2-2 genotype individuals due to their lower macrophage CD163 receptor clearance. 6 Haptoglobin has been a well-known link in disease pathology but has been scarcely examined for its contribution in transplant medicine. The most compelling evidence for a role of Hp genotype in cardiovascular health has been found in both human and animal studies of diabetes mellitus. 6 In liver transplant recipients, donor Hp 2-2 genotype was associated with reduced patient and graft survival. 8 To the best of our knowledge, no previous study has assessed associations between Hp genotype and patient and graft survival after renal transplantation.
The aim of the present study was to investigate the association between Hp 2-2 genotype and cardiovascular mortality, after adjustment for confounders and competing risk from other causes of death. In addition, we assessed associations between Hp 2-2 genotype and all-cause mortality, overall renal graft loss, and death-censored renal graft loss.
Patients and Methods

Study Design, Population, and Setting
This single-center, retrospective cohort study made use of prospectively collected clinical data from medical journals at Oslo University Hospital Rikshospitalet, end point data collected from The Norwegian Renal Registry, and Hp genotypes determined in stored blood samples. Informed consent was obtained from all patients, and the evaluation was reviewed and approved by the institution's medical research review board.
The study was approved by the regional committees for medical and health research ethics in Norway and was performed in accordance with the declarations of Helsinki and Istanbul.
The immunosuppressive standard protocol at Oslo University Hospital Rikshospitalet consisted of a combination of prednisolone, a cell proliferation inhibitor, and a calcineurin inhibitor (cyclosporine A or tacrolimus), with some minor variations in the drugs that have been used during the study period. Induction therapy with basiliximab was given to all patients transplanted in the year 2000 and from 2007 to 2011. Acute rejections were treated with intravenous methylprednisolone followed by an increased dose of oral prednisolone which was tapered over the following 2 months. Steroid-resistant rejections were treated with antithymocyte globulin or anti-CD3 monoclonal antibodies.
Sampling and Data Collection
From a total of 2746 consecutive patients who received a renal transplant at Oslo University Hospital Rikshospitalet, Norway, between September 30, 1999, and October 13, 2011, data on Hp genotype were obtained from 1975 patients. Haptoglobin genotypes were determined using high-performance liquid chromatography (HPLC) at Section of Molecular Diagnostics, Clinical Biochemistry, Aalborg University Hospital, Denmark. We used a modified HPLC method as described previously. 9 In brief, HPLC was performed using an UltiMate 3000 pump, an UltiMate 3000 autosampler, an UltiMate 3000 Variable Wavelength Detector (Dionex Denmark A/S, Hvidovre, Denmark), and an HPLC system manager (Chromeleon Client version 6.80; Dionex Corporation, Sunnyvale, California). For chromatographic separation, a YarraTM 3-mm SEC-3000 column (Phenomenex; Vaerløse, Denmark) was used. To vials containing 30 mL plasma and 5 mL Hb solution (dilution 1:10) followed by the addition of 1255 mL phosphate-buffered saline as the mobile phase. The flow rate was 1 mL/min. Detection of the Hp-Hb complex elution was monitored at wavelength 418 nm. We used human reference plasma with known Hp phenotype (H1511 pooled plasma, H0138 Hp 1-1, and H9762 Hp 2-2. SIGMA; Sigma-Aldrich Denmark a/s, Denmark) for comparison. The Hp phenotype was determined from the curve shape and the relative retention time of the chromatograms.
The end point data for all-cause and cardiovascular mortality and overall graft loss, either due to recipient death or due to death-censored graft loss (return to dialysis and renal retransplantation), were provided by The Norwegian Renal Registry. The registry is based upon annual reports from all nephrology units and includes all patients on renal replacement therapy in Norway. There were less than 1% missing data for included patients. Mortality end points were defined according to the European Renal Association-European Dialysis and Transplant Association causes of death.
Statistical Analysis
Chi-square test, independent t test, and Mann-Whitney U test evaluated the differences in patient characteristics at the time of transplantation between patients with Hp 2-2 genotype and Hp 2-1 or 1-1 genotype as appropriate.
The 2 main statistical approaches in the present study were a proportional hazard regression model for the subdistribution of competing risks with either time to death-censored graft loss or cardiovascular mortality as the outcome variable and standard Cox regression with all-cause mortality or overall renal graft loss as the outcome variable. 10, 11 The observational time started at the time of transplantation. Surviving patients were censored at January 1, 2015. In addition to Hp genotype, the following predefined variables were included in the model: recipient age, gender, donor age, current smoking, atherosclerotic disease (coronary artery disease, cerebrovascular disease, and/or peripheral vascular disease), transplant era (year 1999 through 2006 vs year 2007 through 2011), first or previous renal transplantation, living or deceased donor, preemptive transplantation, time in dialysis therapy prior to transplantation, diabetes mellitus prior to transplantation or posttransplant diabetes mellitus during the first year after transplantation, and type of calcineurin inhibitor (cyclosporine A or tacrolimus) used at 10 weeks after transplantation. We also performed similar analyses in a subgroup consisting of patients who were diagnosed with posttransplant diabetes mellitus during the first year after renal transplantation or had diabetes prior to transplantation (n ¼ 470).
In addition, we assessed differences in biopsy-proven acute rejection rates, as described previously, 12 between Hp genotypes. For 156 patients transplanted during 2010, we had data on histologically verified progression of fibrosis between 6 weeks and 1 year posttransplant. 13 The proportion of progressors and nonprogressors in each Hp genotype was compared. A 2-sided P value <.05 was considered statistically significant.
Results
Demographic and clinical characteristics of the study population are presented in Table 1 . No differences between the Hp 2-2 genotype group and the pooled Hp 2-1 and 1-1 genotype group were found.
Baseline differences between patients included and not included in the present study are described elsewhere.
14 In short, adult patients not included in the study were generally older than the study participants and had slightly more comorbid diseases and less often living donor.
14 Otherwise there were no significant differences between the 2 groups.
During a median follow-up of 7.0 (interquartile range ¼ 4.7-10.5) years, there were 401 deaths, either due to cardiovascular disease (n ¼ 156) or due to other causes (n ¼ 245). A total of 558 renal grafts were lost, either due to recipient death (n¼335) or due to death-censored graft loss (n ¼ 233). Table 2 ). Lack of association between Hp 2-2 genotype and cardiovascular mortality was also found in a subgroup analysis for diabetes prior to transplantation or posttransplant diabetes (SHR 1.06, 95% CI 0.58-1.95; P ¼ .84). In addition, we did not find an association between Hp 2-2 
Mortality
Discussion
The present study found no association between Hp 2-2 genotype and cardiovascular mortality, all-cause mortality, overall renal graft loss, or death-censored graft loss. The distribution of Hp genotypes was similar to previous studies (Hp 1-1: 13.2%, Hp 2-1: 44.5%, Hp 2-2: 42.3%). 15 
Haptoglobin Genotype and CVD
The Hp genotype is one of several factors that might induce oxidative-mediated atherosclerosis, and its role in the development of CVD is not clearly established. 6 Hp 2-2 genotype is positively associated with myocardial infarction risk 16 and negatively associated with coronary bypass graft patency. 17 However, most studies in patients without diabetes have reported neutral or even beneficial associations with Hp 2-2 genotype. 5, 18 In patients with diabetes, the evidence for an association between Hp 2-2 genotype and CVD is stronger. Macrophage clearance of the Hp-Hb complex is slower in Hp 2-2 genotype individuals, leaving more glycated Hb and reactive oxygen species in the circulation. 5 A positive association between Hp 2-2 genotype and the risk of major cardiac events has been recently described, 16 and supplementation of the antioxidant vitamin E lowers the risk of cardiovascular events in diabetic patients with Hp 2-2 genotype. 19 In the present study, we found no association between Hp 2-2 genotype and cardiovascular mortality, not even in the subgroup of patients with diabetes. It should be noted, however, that associations with mortality end points, being crude outcome variables, would not necessarily reflect possible associations between Hp 2-2 genotype and cardiovascular morbidity, including major cardiovascular events. Indeed, previous reports indicate a positive association between Hp 2-2 genotype and development of CVD, while a similar association with cardiovascular mortality has not been shown. Moreover, Hp 2-2 genotype is linked to atherosclerosis. There was a significant association between atherosclerotic disease prior to transplantation and cardiovascular mortality. In multivariable adjusted survival analysis, atherosclerotic disease prior to transplantation was introduced as a confounding variable, while it could also partly be an intermediate variable linking Hp 2-2 genotype to cardiovascular mortality. On the other hand, in univariate analyses, similar associations were found between Hp 2-2 genotype and cardiovascular mortality. Unfortunately, we did not have any data on cardiovascular events in this cohort.
Haptoglobin Genotype and Kidney Disease
Previous reports indicate a positive association between Hp 2-2 genotype and decline in renal function and end-stage renal disease incidence in patients with diabetes. 15, 20 Glomerular filtration of Hp 2-2 proteins increases iron deposition in and damage to renal proximal tubule cells. 21 In patients with end-stage renal disease, Hp 2-2 genotype was associated with higher high-sensitive C-reactive protein levels, indicating a relationship between Hp genotype and inflammation. 22 We found no association between Hp 2-2 genotype and overall or death-censored graft loss. Although most of the Hp proteins are synthesized in the liver, where the recipient genotype determines the Hp protein product, there is some production of Hp proteins in the kidney, which for renal recipients will be determined by the donor Hp genotype. Obviously, this may preclude any associations between recipient Hp genotype and renal graft survival.
Haptoglobin Genotype and Organ Transplantation
In transplant medicine, only a few studies have investigated the role of Hp genotype. In liver transplant recipients that included 450 patients during 3 years' follow-up, donor Hp 2-2 genotype compared to donor Hp 2-1 and 1-1 genotypes was associated with poorer patient and graft survival. 8 Haptoglobin is predominantly synthesized by hepatocytes, hence donor Hp genotype determines which Hp protein will be produced in this patient group. 8 In heart transplant recipients, Hp 2-1 genotype, but not Hp 2-2 genotype, was associated with a higher risk of cardiac transplant vasculopathy. 23 Due to a small sample size, this finding should be interpreted with caution and the biological rationale for an association between Hp 2-1 genotype and cardiac transplant vasculopathy remains unexplained. In renal recipients, Hp 1-1 genotype compared to Hp 2-2 and 2-1 genotype was associated with increased risk of developing cutaneous squamous cell carcinoma. 24 To date, the roles of either recipient or donor Hp genotype for most long-term outcomes after renal transplantation have not been investigated, including patient and graft survival.
Strengths and Limitations
The major strength of the present study is the large cohort from a single center with few missing data. The present study also has several limitations, some of which have been addressed in previous sections. We have no information about donor Hp genotype. The study population almost exclusively consisted of Caucasian patients, and the results may therefore not apply to other ethnic groups. Since Hp genotyping was only performed in patients who attended a clinical visit 10 weeks after renal transplantation, the survival analyses would theoretically also be hampered by immortal time bias, although probably to a limited degree. This bias refers to the period between the time of transplantation and blood sampling at 10 weeks posttransplant, during which death could not have occurred to patients included in the study. The choice of mortality end points might have been to crude to detect an impact of Hp genotypes on cardiovascular health. Finally, we had no information on preexisting cardiovascular disease.
Conclusion
Recipient haptoglobin genotype was not associated with cardiovascular mortality, all-cause mortality, overall, and deathcensored graft loss after renal transplantation, including renal transplant recipients with diabetes mellitus.
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